Skip to content
Find a Provider
Anton P. Porsteinsson, M.D.

Anton P. Porsteinsson, M.D.

Mental Health and Wellness

4.9 out of 5 stars
70 Ratings
13 Comments
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 273-5454
Office (585) 602-5201
Fax (585) 320-1044
Administrative (585) 602-5200

About Me

Dr. Porsteinsson is the Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program (AD-CARE). In addition, he is the first William B. and Sheila Konar Professor of Psychiatry at the University of Rochester, School of Medicine and Dentistry. In 1987, he receive...
Dr. Porsteinsson is the Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program (AD-CARE). In addition, he is the first William B. and Sheila Konar Professor of Psychiatry at the University of Rochester, School of Medicine and Dentistry. In 1987, he received his MD degree from the University of Iceland School of Medicine and came to the University of Rochester in 1989, where he completed his internship and residency. He is Board certified in Psychiatry, with added qualifications in Geriatric Psychiatry.
Dr. Porsteinsson has devoted his career to the care and study of individuals with memory disorders. He participates in the University of Rochester Memory Care Program, which serves a population with memory disorders. Internationally recognized in clinical research and considered one of the leading experts in Alzheimer's disease and dementia, his interests lie in biomarkers, imaging, and novel pharmacologic agents in the treatment of Alzheimer's disease and other dementias, both in terms of cognitive loss and behavioral disturbances. He is a leading investigator for many prominent national Alzheimer's prevention and treatment trials and has conducted major clinical trials with cognitive enhancers and course stabilizing agents in dementia, as well as psychotropics for behavioral changes associated with dementia. Dr. Porsteinsson is the author and collaborator of hundreds of research publications and serves as site principal investigator for research grants from the National Institutes of Health and other leading funders.

Faculty Appointments

Professor - Department of Psychiatry, Geriatric/Psychiatry (SMD)

William and Sheila Konar Endowed Professor - Department of Psychiatry (SMD)

Professor - Department of Medicine, Geriatrics/Aging (SMD) - Joint

Professor - Department of Neurology, Memory Care (SMD) - Joint

Professor - Department of Neuroscience (SMD) - Joint

Credentials

Residency & Fellowship

Residency, Psychiatry, University of Rochester Medical Center. 1990 - 1993

Internship, University of Rochester Medical Center. 1989 - 1990

Internship, University of Iceland, Reykjavik. 1987 - 1989

Awards

Listed in Editions of America's Top Doctors. 2012

Listed in editions of Distinguished Professionals. 2010

Listed in editions of The Global Directory of Who's Who. 2010

Dr. John Baum Award, University of Rochester School of Medicine and Dentistry. 2009

Listed in editions of Who's Who in America. 2007

Summer Research Institute Fellowship. 1999

The Helga Jonsdottir and Sigurlidi Kristjansson Memorial Award. 1997

Carl Albert Jaenike Award. 1993

Residents' Recognition Award. 1993

Consultation-Liaison Award. 1992

Thorvaldur Thoroddsens Memorial Award. 1981

P.O. Christensens Memorial Award. 1981

Research

Research Lab

Publications

Journal Articles

Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment.

Butler PM, Yang J, Brown R, Hobbs M, Becker A, Penalver-Andres J, Syz P, Muller S, Cosne G, Juraver A, Song HH, Saha-Chaudhuri P, Roggen D, Scotland A, Silveira N, Demircioglu G, Gabelle A, Hughes R, Erkkinen MG, Langbaum JB, Lingler JH, Price P, Quiroz YT, Sha SJ, Sliwinski M, Porsteinsson AP, Au R, Bianchi MT, Lenyoun H, Pham H, Patel M, Belachew S

Nature medicine.. 2025 March 4 Epub 03/04/2025.

Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.

Coleman KKL, Berry S, Cummings J, Hsiung GR, Laforce R, Huey E, Ducharme S, Tartaglia MC, Mendez MF, Onyike C, Domoto-Reilly K, Masellis M, Herrmann N, Porsteinsson A, Detry MA, Stewart C, Bosse AL, McGlothlin A, Dias B, Pandey S, Mayich M, Pasternak SH, Ruiz Garcia R, Restrepo-Martinez M, Feldman H, Boxer AL, Finger EC

The Lancet. Neurology.. 2025 February 24 (2):128-139. Epub 1900 01 01.

Dynamic proportional loss of functional connectivity revealed change of left superior frontal gyrus in subjective cognitive decline: an explanatory study based on Chinese and Western cohorts.

Wang L, Hu W, Dong F, Sheng C, Wu J, Han Y, Jiang J, Weiner MW, Aisen P, Petersen R, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Shaw LM, Khachaturian Z, Sorensen G, Kuller L, Raichle M, Paul S, Davies P, Fillit H, Hefti F, Holtzman D, Mesulam MM, Potter W, Snyder P, Schwartz A, Montine T, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Jiminez G, Harvey D, Bernstein M, Thompson P, Schuff N, Borowski B, Gunter J, Senjem M, Vemuri P, Jones D, Kantarci K, Ward C, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Landau S, Cairns NJ, Householder E, Taylor-Reinwald L, Lee V, Korecka M, Figurski M, Crawford K, Neu S, Foroud TM, Potkin SG, Shen L, Faber K, Kim S, Nho K, Thal L, Buckholtz N, Albert M, Frank R, Hsiao J, Kaye J, Quinn J, Lind B, Carter R, Dolen S, Schneider LS, Pawluczyk S, Beccera M, Teodoro L, Spann BM, Brewer J, Vanderswag H, Fleisher A, Heidebrink JL, Lord JL, Mason SS, Albers CS, Knopman D, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Rountree S, Dang M, Stern Y, Honig LS, Bell KL, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Oliver A, Marson D, Griffith R, Clark D, Geldmacher D, Brockington J, Roberson E, Grossman H, Mitsis E, de Toledo-Morrell L, Shah RC, Duara R, Varon D, Greig MT, Roberts P, Onyike C, D'Agostino D, Kielb S, Galvin JE, Cerbone B, Michel CA, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy P, Petrella JR, Wong TZ, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Sinha P, Oates E, Conrad G, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein BS, Martin K, Makino KM, Ismail M, Brand C, Mulnard RA, Thai G, McAdams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Tingus K, Woo E, Silverman DHS, Lu PH, Bartzokis G, Graff-Radford NR, Parfitt F, Kendall T, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, Hunt C, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Hsiung GR, Feldman H, Mudge B, Assaly M, Bernick C, Munic D, Kertesz A, Rogers J, Trost D, Kerwin D, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Lane B, Rosen A, Tinklenberg J, Sabbagh MN, Belden CM, Jacobson SA, Sirrel SA, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Allard J, Lerner A, Ogrocki P, Hudson L, Fletcher E, Carmichae O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Preda A, Nguyen D, Tariot P, Reeder S, Bates V, Capote H, Rainka M, Scharre DW, Kataki M, Adeli A, Zimmerman EA, Celmins D, Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Kitzmiller TJ, Schwartz ES, Sink KM, Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Spicer K, Bachman D, Pasternak S, Rachinsky I, Drost D, Pomara N, Hernando R, Sarrael A, Schultz SK, Ponto LLB, Shim H, Smith KE, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Raj BA, Neylan T, Grafman J, Davis M, Morrison R, Hayes J, Finley S, Friedl K, Fleischman D, Arfanakis K, James O, Massoglia D, Fruehling J, Harding S, Peskind ER, Petrie EC, Li G, Yesavage JA, Taylor JL, Furst AJ

GeroScience.. 2025 January 31 Epub 01/31/2025.

Sex differences in interacting genetic and functional connectivity biomarkers in Alzheimer's disease.

Williamson JN, James SA, Mullen SP, Sutton BP, Wszalek T, Mulyana B, Mukli P, Yabluchanskiy A, Yang Y

GeroScience.. 2024 December 46 (6):6071-6084. Epub 04/10/2024.

Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.

Tumati S, Herrmann N, Perin J, Rosenberg PB, Lerner AJ, Mintzer J, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Shade D, Lanctôt KL

International psychogeriatrics. 2024 December 36 (12):1232-1244. Epub 09/19/2024.

Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.

Tumati S, Herrmann N, Perin J, Rosenberg PB, Lerner AJ, Mintzer J, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Shade D, Lanctôt KL

International psychogeriatrics. 2024 December 36 (12):1232-1244. Epub 1900 01 01.

iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer's disease.

Zivko C, Sagar R, Xydia A, Lopez-Montes A, Mintzer J, Rosenberg PB, Shade DM, Porsteinsson AP, Lyketsos CG, Mahairaki V

Molecular psychiatry.. 2024 November 29 (11):3644-3652. Epub 06/05/2024.

MRI Signature of ?-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population.

Wisse LEM, Spotorno N, Rossi M, Grothe MJ, Mammana A, Tideman P, Baiardi S, Strandberg O, Ticca A, van Westen D, Mattsson-Carlgren N, Palmqvist S, Stomrud E, Parchi P, Hansson O,

JAMA neurology.. 2024 October 181 (10):1051-1059. Epub 1900 01 01.

Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease.

Lee D, Clark ED, Antonsdottir IM, Porsteinsson AP

Journal of the American Medical Directors Association.. 2024 October 25 (10):105173. Epub 07/22/2024.

Neuropsychiatric symptoms in cognitive decline and Alzheimer's disease: biomarker discovery using plasma proteomics.

Rabl M, Clark C, Dayon L, Popp J,

Journal of neurology, neurosurgery, and psychiatry.. 2024 September 17 Epub 09/17/2024.

Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration.

Kim KY, Kim E, Lee JY

Alzheimer's research & therapy.. 2024 September 1216 (1):202. Epub 09/12/2024.

Towards cascading genetic risk in Alzheimer's disease.

Altmann A, Aksman LM, Oxtoby NP, Young AL, , Alexander DC, Barkhof F, Shoai M, Hardy J, Schott JM

Brain : a journal of neurology.. 2024 August 1147 (8):2680-2690. Epub 1900 01 01.

Correction: Polygenic effects on the risk of Alzheimer's disease in the Japanese population.

Kikuchi M, Miyashita A, Hara N, Kasuga K, Saito Y, Murayama S, Kakita A, Akatsu H, Ozaki K, Niida S, Kuwano R, Iwatsubo T, Nakaya A, Ikeuchi T

Alzheimer's research & therapy.. 2024 July 1016 (1):158. Epub 07/10/2024.

Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).

Zeng L, Perin J, Gross AL, Shade D, Lanctôt KL, Lerner AJ, Mintzer JE, Brawman-Mintzer O, Padala PR, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Herrmann N, Rosenberg PB

International journal of geriatric psychiatry.. 2024 June 39 (6):e6108. Epub 1900 01 01.

Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains.

Quesnel MJ, Labonté A, Picard C, Zetterberg H, Blennow K, Brinkmalm A, Villeneuve S, Poirier J

Brain : a journal of neurology.. 2024 May 3147 (5):1680-1695. Epub 1900 01 01.

Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer's disease: a novel small molecule with disease modifying potential.

Lee D, Antonsdottir IM, Clark ED, Porsteinsson AP

Expert opinion on pharmacotherapy.. 2024 May 25 (7):791-799. Epub 05/30/2024.

Sex-specific modulation of amyloid-? on tau phosphorylation underlies faster tangle accumulation in females.

Wang YT, Therriault J, Servaes S, Tissot C, Rahmouni N, Macedo AC, Fernandez-Arias J, Mathotaarachchi SS, Benedet AL, Stevenson J, Ashton NJ, Lussier FZ, Pascoal TA, Zetterberg H, Rajah MN, Blennow K, Gauthier S, Rosa-Neto P

Brain : a journal of neurology.. 2024 April 4147 (4):1497-1510. Epub 1900 01 01.

Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort.

Oka T, Matsuzawa Y, Tsuneyoshi M, Nakamura Y, Aoshima K, Tsugawa H

Scientific reports.. 2024 April 214 (1):6797. Epub 04/02/2024.

A novel spatiotemporal graph convolutional network framework for functional connectivity biomarkers identification of Alzheimer's disease.

Zhang Y, Xue L, Zhang S, Yang J, Zhang Q, Wang M, Wang L, Zhang M, Jiang J, Li Y

Alzheimer's research & therapy.. 2024 March 1416 (1):60. Epub 03/14/2024.

Polygenic effects on the risk of Alzheimer's disease in the Japanese population.

Kikuchi M, Miyashita A, Hara N, Kasuga K, Saito Y, Murayama S, Kakita A, Akatsu H, Ozaki K, Niida S, Kuwano R, Iwatsubo T, Nakaya A, Ikeuchi T

Alzheimer's research & therapy.. 2024 February 2716 (1):45. Epub 02/27/2024.

Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer's disease: an exploratory study of F-FDG-PET.

Zhang Q, Fan C, Wang L, Li T, Wang M, Han Y, Jiang J

GeroScience.. 2024 February 46 (1):1407-1420. Epub 08/23/2023.

APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in ?4/?4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics.

Abushakra S, Porsteinsson AP, Sabbagh M, Watson D, Power A, Liang E, MacSweeney E, Boada M, Flint S, McLaine R, Kesslak JP, Hey JA, Tolar M

Alzheimer's & dementia : translational research & clinical interventions.. 2024 10 (3):e12498. Epub 08/13/2024.

Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.

Shirzadi Z, Schultz SA, Yau WW, Joseph-Mathurin N, Fitzpatrick CD, Levin R, Kantarci K, Preboske GM, Jack CR, Farlow MR, Hassenstab J, Jucker M, Morris JC, Xiong C, Karch CM, Levey AI, Gordon BA, Schofield PR, Salloway SP, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Day GS, Koeppe R, Chui HC, Berman S, Mori H, Sanchez-Valle R, Lee JH, Rosa-Neto P, Ruthirakuhan M, Wu CY, Swardfager W, Benzinger TLS, Sohrabi HR, Martins RN, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Schultz AP, Chhatwal JP,

JAMA neurology.. 2023 December 180 (12):1353-1363. Epub 1900 01 01.

Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial.

Lanctôt KL, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, Mintzer J, Rosenberg PB, Shade D, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey AI, Padala KP, Herrmann N

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2023 December 31 (12):1077-1087. Epub 06/15/2023.

Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.

Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS

The New England journal of medicine.. 2023 November 16389 (20):1862-1876. Epub 1900 01 01.

Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).

Lanctôt KL, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer RW, Vieira D, Coulibaly H, Rosenberg PB, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Burke WJ, Mintzer J, Herrmann N

International psychogeriatrics. 2023 November 35 (11):664-672. Epub 04/17/2023.

Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data.

Jo T, Kim J, Bice P, Huynh K, Wang T, Arnold M, Meikle PJ, Giles C, Kaddurah-Daouk R, Saykin AJ, Nho K

EBioMedicine.. 2023 November 97 :104820. Epub 10/07/2023.

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.

Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, Sanabria Bohorquez SM, Anania VG, Wildsmith KR, Schauer SP, Lee J, Dolton MJ, Ramakrishnan V, Abramzon D, Teng E

Neurology.. 2023 October 3101 (14):e1391-e1401. Epub 08/29/2023.

Trial of Solanezumab in Preclinical Alzheimer's Disease.

Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS

The New England journal of medicine.. 2023 September 21389 (12):1096-1107. Epub 07/17/2023.

Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.

Bocancea DI, Svenningsson AL, van Loenhoud AC, Groot C, Barkhof F, Strandberg O, Smith R, La Joie R, Rosen HJ, Pontecorvo MJ, Rabinovici GD, van der Flier WM, Hansson O, Ossenkoppele R

Brain : a journal of neurology.. 2023 September 1146 (9):3719-3734. Epub 1900 01 01.

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM

JAMA.. 2023 August 8330 (6):512-527. Epub 1900 01 01.

Prevalence and Clinical Implications of a ?-Amyloid-Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease.

Erickson P, Simrén J, Brum WS, Ennis GE, Kollmorgen G, Suridjan I, Langhough R, Jonaitis EM, Van Hulle CA, Betthauser TJ, Carlsson CM, Asthana S, Ashton NJ, Johnson SC, Shaw LM, Blennow K, Andreasson U, Bendlin BB, Zetterberg H

JAMA neurology.. 2023 July 3180 (9):969-79. Epub 07/31/2023.

Prognostic relevance of gait-related cognitive functions for dementia conversion in amnestic mild cognitive impairment.

Tuena C, Maestri S, Serino S, Pedroli E, Stramba-Badiale M, Riva G

BMC geriatrics.. 2023 July 3123 (1):462. Epub 07/31/2023.

Identifying healthy individuals with Alzheimer's disease neuroimaging phenotypes in the UK Biobank.

Azevedo T, Bethlehem RAI, Whiteside DJ, Swaddiwudhipong N, Rowe JB, Lió P, Rittman T

Communications medicine.. 2023 July 203 (1):100. Epub 07/20/2023.

Association Between False Memories and Delusions in Alzheimer Disease.

McLachlan E, Ocal D, Burgess N, Reeves S, Howard R

JAMA psychiatry.. 2023 July 180 (7):700-709. Epub 1900 01 01.

Associations between neuropsychiatric symptoms of affective and vegetative domains and brain morphology in aging people with mild cognitive impairment and Alzheimer's disease.

Cannizzaro A, Ronat L, El Haffaf LM, Hanganu A

International journal of geriatric psychiatry.. 2023 June 38 (6):e5952. Epub 1900 01 01.

Deep learning-based polygenic risk analysis for Alzheimer's disease prediction.

Zhou X, Chen Y, Ip FCF, Jiang Y, Cao H, Lv G, Zhong H, Chen J, Ye T, Chen Y, Zhang Y, Ma S, Lo RMN, Tong EPS, Mok VCT, Kwok TCY, Guo Q, Mok KY, Shoai M, Hardy J, Chen L, Fu AKY, Ip NY

Communications medicine.. 2023 April 63 (1):49. Epub 04/06/2023.

A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.

Lee D, Clark ED, Antonsdottir IM, Porsteinsson AP

Expert opinion on pharmacotherapy.. 2023 April 24 (6):691-703. Epub 03/28/2023.

Effect of online tDCS to left somatomotor cortex on neuropsychiatric symptoms among older adults at risk for dementia.

Turnbull A, Anthony M, Tadin D, Porsteinsson AP, Heffner K, Lin FV

Cortex; a journal devoted to the study of the nervous system and behavior.. 2023 February 159 :131-141. Epub 12/17/2022.

Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.

Öhrfelt A, Benedet AL, Ashton NJ, Kvartsberg H, Vandijck M, Weiner MW, Trojanowski JQ, Shaw LM, Zetterberg H, Blennow K

Neurology.. 2023 January 17100 (3):e275-e285. Epub 10/03/2022.

A data-driven examination of apathy and depressive symptoms in dementia with independent replication.

Vasconcelos Da Silva M, Melendez-Torres GJ, Ismail Z, Testad I, Ballard C, Creese B

Alzheimer's & dementia : diagnosis, assessment & disease monitoring.. 2023 15 (1):e12398. Epub 02/05/2023.

Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study.

Clark ED, Perin J, Herrmann N, Brawman-Mintzer O, Lanctôt KL, Lerner AJ, Mintzer J, Padala PR, Rosenberg PB, Sami S, Shade DM, van Dyck CH, Porsteinsson AP

Alzheimer's & dementia : translational research & clinical interventions.. 2023 9 (3):e12403. Epub 08/02/2023.

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease.

Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D, Strandberg O, Janelidze S, Palmqvist S, Mattsson-Carlgren N, Smith R, Stomrud E, Ossenkoppele R, Hansson O

Nature communications.. 2022 November 413 (1):6635. Epub 11/04/2022.

Alzheimer's disease and related dementias: From risk factors to disease pathogenesis.

Porsteinsson AP, Rangaraju S, Spires-Jones TL, O'Banion MK

The European journal of neuroscience.. 2022 November 56 (9):5337-5341. Epub 11/10/2022.

The trend of disruption in the functional brain network topology of Alzheimer's disease.

Fathian A, Jamali Y, Raoufy MR

Scientific reports.. 2022 September 212 (1):14998. Epub 09/02/2022.

The Polygenic Risk Score Knowledge Base offers a centralized online repository for calculating and contextualizing polygenic risk scores.

Page ML, Vance EL, Cloward ME, Ringger E, Dayton L, Ebbert MTW, Miller JB, Kauwe JSK

Communications biology.. 2022 September 25 (1):899. Epub 09/02/2022.

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.

Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA

JAMA neurology.. 2022 August 179 (8):758-767. Epub 1900 01 01.

Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment.

Jiang J, Sheng C, Chen G, Liu C, Jin S, Li L, Jiang X, Han Y

GeroScience.. 2022 August 44 (4):2319-2336. Epub 05/18/2022.

An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-?4 in female patients with Alzheimer's disease.

Jiang Y, Zhou X, Wong HY, Ouyang L, Ip FCF, Chau VMN, Lau SF, Wu W, Wong DYK, Seo H, Fu WY, Lai NCH, Chen Y, Chen Y, Tong EPS, Mok VCT, Kwok TCY, Mok KY, Shoai M, Lehallier B, Losada PM, O'Brien E, Porter T, Laws SM, Hardy J, Wyss-Coray T, Masters CL, Fu AKY, Ip NY

Nature aging.. 2022 July 2 (7):616-634. Epub 07/15/2022.

Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume.

Milicic L, Vacher M, Porter T, Doré V, Burnham SC, Bourgeat P, Shishegar R, Doecke J, Armstrong NJ, Tankard R, Maruff P, Masters CL, Rowe CC, Villemagne VL, Laws SM

GeroScience.. 2022 June 44 (3):1807-1823. Epub 04/21/2022.

Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression.

Wen J, Fu CHY, Tosun D, Veturi Y, Yang Z, Abdulkadir A, Mamourian E, Srinivasan D, Skampardoni I, Singh A, Nawani H, Bao J, Erus G, Shou H, Habes M, Doshi J, Varol E, Mackin RS, Sotiras A, Fan Y, Saykin AJ, Sheline YI, Shen L, Ritchie MD, Wolk DA, Albert M, Resnick SM, Davatzikos C

JAMA psychiatry.. 2022 May 179 (5):464-474. Epub 1900 01 01.

Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease.

Duong MT, Das SR, Lyu X, Xie L, Richardson H, Xie SX, Yushkevich PA, Wolk DA, Nasrallah IM

Nature communications.. 2022 March 2113 (1):1495. Epub 03/21/2022.

Dissection of the polygenic architecture of neuronal A? production using a large sample of individual iPSC lines derived from Alzheimer's disease patients.

Kondo T, Hara N, Koyama S, Yada Y, Tsukita K, Nagahashi A, Ikeuchi T, Ishii K, Asada T, Arai T, Yamada R, Inoue H

Nature aging.. 2022 February 2 (2):125-139. Epub 02/17/2022.

Sex Modulates the Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment.

Yang Z, Caldwell JZK, Cummings JL, Ritter A, Kinney JW, Cordes D

Frontiers in psychiatry.. 2022 13 :804168. Epub 04/05/2022.

A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer's disease.

Inglese M, Patel N, Linton-Reid K, Loreto F, Win Z, Perry RJ, Carswell C, Grech-Sollars M, Crum WR, Lu H, Malhotra PA, Aboagye EO

Communications medicine.. 2022 2 :70. Epub 06/20/2022.

A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure.

Yang Z, Nasrallah IM, Shou H, Wen J, Doshi J, Habes M, Erus G, Abdulkadir A, Resnick SM, Albert MS, Maruff P, Fripp J, Morris JC, Wolk DA, Davatzikos C

Nature communications.. 2021 December 312 (1):7065. Epub 12/03/2021.

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status.

Shen XN, Huang YY, Chen SD, Guo Y, Tan L, Dong Q, Yu JT

Translational psychiatry.. 2021 November 1311 (1):585. Epub 11/13/2021.

Insula and Inferior Frontal Gyrus' Activations Protect Memory Performance Against Alzheimer's Pathology in Old Age. .

Lin F, Ren P, Lo Y, Chapman B, Jacobs A, Baran T, Porsteinsson AP, Foxe J.

J Alzheimers Dis. 2017; 55(2): 669-678.

The Cingulate Cortex of Older Adults with Excellent Memory Capacity

Lin F, Ren P, Mapstone M, Meyers S, Porsteinsson AP, Baran TM.

Cortex. 2017; : 83-92.

Changes in Neuropsychiatric Inventory associated with semagestat treatment of Alzheimer's disease.

Rosenberg PB; Lanctot KL; Herrmann N; Mintzer JE; Porsteinsson AP; Sun X; Raman R.

J Alzheimers Disease. 2016; 54(1): 373-81.

Cognitive and Neural Effects of Vision-Based Speed of Processing Training in Older Adults with Mild Cognitive Impairment: A pilot study

Lin F, Heffner K, Tivarus M, Ren P, Brasch J, Chen D, Mapstone M, Porsteinsson AP, and Tadin D.

J Am Geriatr Soc. 2016; 64(6): 1293-8.

Citalopram for the Treatment of Agitation in Alzheimer's Dementia: Genetic Influences.

Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, MD8, Lyketsos CG, and Avramopoulos D: For the CitAD Research Group.

J Geriatr Psychiatry Neurol. 2016; 29(2): 59-64.

ERP C250 Shows the Elderly (Cognitively Normal, Alzheimer's Disease) Store More Stimuli in Short-Term Memory than Young Adults Do.

Chapman R, Gardner MN, Mapstone M, Klorman R, Porsteinsson AP, Dupree HM, Antonsdottir IM, Kamalyan L.

Clinical Neurophysiology 127. 2016; : 2423–2435.

Trajectories of neuropsychiatric symptoms and cognitive decline in mild cognitive impairment.

David N, Lin F, Porsteinsson AP.

Am J Geriatr Psychiatry. 2016; 24(1): 70-80.

Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence from the CitAD Study

Leonpacher A, Peters ME, Drye LT, Makino KM, Newell J, Devanand DP, Frangakis C, Mintzer JE, Munro CA, Pollock BG, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Porsteinsson AP: For the CitAD Research Group.

Am J Psychiatry. 2016; 173(5): 473-80.

Heterogeneity of Treatment Response to Citalopram for Alzheimer Disease Patients with Aggression or Agitation: The CitAD Randomized Clinical Trial.

Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano C, Mintzer JE, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, Rosenberg PB, Shade DM, Weintraub D, Yesavage J, and Lyketsos CG, for the CitAD Research Group.

Am J Psychiatry. 2016; 173(5): 465-72.

Dazed and Confused - Medical Cannabis in Alzheimer's Disease.

Antonsdottir IM, Makino KM, Porsteinsson AP.

Am J Geriatr Psychiatry. 2016; 24(11): 1004-06.

Clinical Benefit of Tramiprosate in AD are associated with higher number of APOE4 alleles: "The Gene-Dose Effect"

Abushakra S, Porsteinsson AP, Vellas B, et al.

J Prev Alz Dis. 2016; 3(4): 219-228.

Change in Agitation in Alzheimer's disease in the placebo arm of a 9-week controlled trial.

Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; and Lyketsos CG, for the CitAD Research Group.

Int Psychogeriatric. 2015; 27(12): 2059-67.

Time to response to citalopram treatment for agitation in Alzheimer's disease

Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Yesavage J, and Lyketsos CG, for the CitAD Research Group.

Am J Geriatr Psychiatry. 2015; 23(11): 1127-33.

Dextromethorphan/Quinidine (DM/Q) for Agitation/Aggression in Alzheimer's Disease Dementia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Cummings J, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gandara JE, Agronin M, Davis CS, Nguyen U, Shin P, Tariot PN, and Siffert J, for the 12-AVR-131 Study Group.

JAMA. 2015; 314(12): 1242-1254.

Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders.

Profenno LA, Porsteinsson AP, Faraone SV

Biological psychiatry.. 2010 March 1567 (6):505-12. Epub 04/09/2009.

Predicting Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Neuropsychological Tests and Multivariate Methods.

Chapman, AP.; Mapstone, M.; McCrary, J.W.; Gardner, M.N.; Porsteinsson, A.P.

Journal of Clinical and Experimental Neuropsychology. 2010; 13: 1-13.

Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML,

Neurology.. 2008 November 1871 (21):1702-8. Epub 1900 01 01.

Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.

, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M

Archives of neurology.. 2008 July 65 (7):896-905. Epub 05/12/2008.

A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.

Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2008 July 16 (7):537-50. Epub 1900 01 01.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT,

Current Alzheimer research.. 2008 February 5 (1):83-9. Epub 1900 01 01.

Memantine in the treatment of mild-to-moderate Alzheimer's disease.

Cosman KM, Boyle LL, Porsteinsson AP

Expert opinion on pharmacotherapy.. 2007 February 8 (2):203-14. Epub 1900 01 01.

Design of Depression in Alzheimer's Disease Study-2.

Martin BK, Frangakis CE, Rosenberg PB, Mintzer JE, Katz IR, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Niederehe G, Lyketsos CG

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2006 November 14 (11):920-30. Epub 1900 01 01.

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC

Neurology.. 2006 February 2866 (4):602-4. Epub 1900 01 01.

Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly.

Porsteinsson AP

Drugs & aging.. 2006 23 (11):877-86. Epub 1900 01 01.

A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease.

Profenno LA, Jakimovich L, Holt CJ, Porsteinsson A, Tariot PN

Current Alzheimer research.. 2005 December 2 (5):553-8. Epub 1900 01 01.

Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.

Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L, ,

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2005 November 13 (11):942-9. Epub 1900 01 01.

Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'.

Rosenberg PB, Onyike CU, Katz IR, Porsteinsson AP, Mintzer JE, Schneider LS, Rabins PV, Meinert CL, Martin BK, Lyketsos CG,

International journal of geriatric psychiatry.. 2005 February 20 (2):119-27. Epub 1900 01 01.

Memantine – A Novel Therapeutic Option for Alzheimer's Disease.

Porsteinsson AP; Ismail MS.

Today's Therapeutic Trends. 2004; 22(1): 17-28.

Choosing treatment for Alzheimer's patients and their caregivers.

Schneider LS, Porsteinsson AP, Peskin ER, Pfeiffer EA

Geriatrics.. 2003 August 58 Suppl 1 :3-18, 23; quiz 19-22. Epub 1900 01 01.

Valproate therapy for agitation in dementia: open-label extension of a double-blind trial.

Porsteinsson AP, Tariot PN, Jakimovich LJ, Kowalski N, Holt C, Erb R, Cox C

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2003 11 (4):434-40. Epub 1900 01 01.

Dementia management: regulations, rules, and research.

Tune LE, Porsteinsson A, Weinberg A

Journal of the American Medical Directors Association.. 2003 4 (4 Suppl):H13-6. Epub 1900 01 01.

Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.

Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S

Advanced drug delivery reviews.. 2002 December 754 (12):1567-77. Epub 1900 01 01.

Interactive grand rounds: mood stabilizers in dementia.

Nelson JC, Tune LE, Daiello LA, Porsteinsson A

Geriatrics.. 2002 September 57 (9):suppl 2-5. Epub 1900 01 01.

Pharmacologic therapy for behavioral symptoms of Alzheimer's disease.

Tariot PN, Ryan JM, Porsteinsson AP, Loy R, Schneider LS

Clinics in geriatric medicine.. 2001 May 17 (2):359-76. Epub 1900 01 01.

Second generation anticonvulsant medications: their use in children.

Noviasky JA, Porsteinsson AP, Lee YH

The Journal of school nursing : the official publication of the National Association of School Nurses.. 2001 April 17 (2):103-11. Epub 1900 01 01.

Placebo-controlled study of divalproex sodium for agitation in dementia.

Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, Noviasky J, Kowalski N, Holt CJ, Irvine C

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2001 9 (1):58-66. Epub 1900 01 01.

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C

Neurology.. 2000 June 2754 (12):2269-76. Epub 1900 01 01.

Reconsidering the DSM-IV diagnoses of Alzheimer's disease: behavioral and psychological symptoms in patients

Caine ED; Porsteinsson A; Lyness JM; First M;.

International Psychogeriatrics. 2000; 12(1): 23-27.

Mood Disturbances in Alzheimer's Disease.

Porsteinsson AP, Tariot PN, Schneider LS

Seminars in clinical neuropsychiatry.. 1997 October 2 (4):265-275. Epub 1900 01 01.

Treating Alzheimer's disease. Pharmacologic options now and in the near future.

Tariot PN, Schneider L, Porsteinsson AP

Postgraduate medicine.. 1997 June 101 (6):73-6, 81, 84 passim. Epub 1900 01 01.

Suicide and Alcoholism: Distinguishing Alcoholics with and without Comorbid Drug Abuse.

Porsteinsson, A.; Duberstein, P.; Conwell, Y.; Cox, C.; Forbes, N.; Caine, E.D.

American Journal of Addictions. 1997; 6: 304-310.

An open trial of valproate for agitation in geriatric neuropsychiatric disorders.

Porsteinsson AP, Tariot PN, Erb R, Gaile S

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 1997 5 (4):344-51. Epub 1900 01 01.

Suicide and alcoholism. Distinguishing alcoholic patients with and without comorbid drug abuse.

Porsteinsson A, Duberstein PR, Conwell Y, Cox C, Forbes N, Caine ED

The American journal on addictions. 1997 6 (4):304-10. Epub 1900 01 01.

Treatment of agitation in dementia.

Tariot P, Gaile SE, Castelli NA, Porsteinsson AP

New directions for mental health services. 1997 (76):109-23. Epub 1900 01 01.

Thyroid evaluation of hospitalized psychiatric patients: the role of TSH screening for thyroid dysfunction.

Woolf PD, Nichols D, Porsteinsson A, Boulay R

Thyroid : official journal of the American Thyroid Association.. 1996 October 6 (5):451-6. Epub 1900 01 01.

Measurement of Behavioral Disturbance in Chronic Care Populations.

Tariot PN; Teri L; Porsteinsson A; Weiner;.

Journal of Mental Health Aging. 1996; 2(3): 213-229.

Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Alzheimer's Disease.

Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD.

Neurology. .

Depression and Cognitive Disorders in Older Primary Care Patients.

Boyle LL; Porsteinsson AP; Cui X; King DA; Lyness JM.

Journal of Clinical Psychiatry. .

Books

Neurodegenerative Dementias (1999)

Chapter: Nursing Homes and Long Term Care.

Authors: Porsteinsson, AP; Tariot, PN;

Publisher: McGraw-Hill Companies, New York 1999

Measurement in Elderly Chronic Care Populations (1997)

Chapter: Measurement of Behavioral Disturbances in Chronic Care Populations.

Authors: Tariot, PN; Porsteinsson, AP; Teri L; Weiner MF;

Publisher: Springer Publishing Company, Incorporated, New York 1997

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Concern the care provider showed for your questions or worries

4.9 stars

Care provider's efforts to include you in decisions about your care

4.9 stars

Explanations the care provider gave you about your problem or condition

4.9 stars

Likelihood of recommending this care provider to others

4.9 stars

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.9 stars

Patient Comments

Good

Dec 08, 2024

5.0 stars

Very pleased with Dr. Porsteinsson

Sep 22, 2024

5.0 stars

Dr. Anton is one of the best doctors of any specialty I have ever encountered.

Apr 29, 2024

5.0 stars

Glad to have Dr P as my provider

Apr 28, 2024

5.0 stars

[...] If I were to recommend treatment for someone else, I would refer them to the office not to this provider.

Apr 15, 2024

5.0 stars

Good.

Sep 05, 2023

5.0 stars

We/you are so blessed & fortunate to have Dr. Anton as a provider. Without equal to any provider I've worked with professionally, or experienced as a provider in my 60 years of nursing practice!!.

Aug 10, 2023

5.0 stars

I have recommended him several times. I believe he is the best specialist for dementia in town.

Aug 09, 2023

5.0 stars

Dr. P is one of the best specialists I've seen. He's my neurologist for life!

Aug 02, 2023

5.0 stars

Good experience.

Jul 13, 2023

5.0

He is a great dr.

Jul 12, 2023

5.0

I think Dr. P is world class. He and his team are helping us through a very difficult time.

Feb 21, 2022

5.0

This will be a long treatment issue and provider was very good at explaining that.

Feb 02, 2022